

A study to determine the efficacy of a topically applied artemether gel in the treatment of senile warts.

Submission date 13/02/2015	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 25/02/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 15/06/2016	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Senile warts are benign skin tumours. They are removed by invasive, unpleasant methods (curettage, cryotherapy, laser, surgery) with certain risks (e.g. infection, depigmentation). This clinical proof of concept study aims to assess the efficacy of an artemether topical formulation in the treatment of senile warts.

Who can participate?

Each participant must have at least 8 flat or slightly elevated senile warts.

What does the study involve?

The test product will be applied twice daily for up to 8 weeks. Five lesions per study participant will be treated with study medication and 3 will serve as reference lesions. The assessment of efficacy will be performed on the photographs taken at the beginning and the treatment and study end by applying a regression score and by measuring the longest axis of lesion.

What are the possible benefits and risks of participating?

The potential benefit for participants is a painless, non-invasive treatment leading to regression or clearance of seborrheic keratosis. Development of adverse events like pruritis, erythema are possible risks associated with the treatment.

Where is the study run from?

The study will be carried out in a dermatology clinic.

When is the study starting and how long is it expected to run for?

From February 2015 to July 2015.

Who is funding the study?

EpiPharm AG

Who is the main contact?
Dr Rosemarie Sift Carter

Contact information

Type(s)
Public

Contact name
Dr Rosemarie Sift Carter

Contact details
Hauptstrasse 67
Binningen
Switzerland
4102

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
EPI-02

Study information

Scientific Title
Single centre, open-label, intra-individual, comparison, proof of concept study to determine the efficacy of an artemether topical formulation in subjects with seborrheic keratosis

Study objectives
Treatment of seborrheic keratosis with artemether will lead to regression of the lesions compared to no treatment.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethic Committee of North-Western and Central Switzerland, 17/01/2015, reference number: EKNZ 2014-390

Study design
Open-label intra-individual comparison proof-of-concept study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Seborrheic keratosis

Interventions

Interventions as of 15/06/2016:

A total of 8 lesions per subject are identified at visit 1 (day 1), 5 of them are allocated to artemether treatment and 3 serve as reference lesions. Artemether 3% is to be administered for a duration of 8 weeks twice daily (i.e. in the morning and evening). The study lesions will be assessed at baseline visit (day 1) and at treatment end and follow-up/study end visits (day 56 and day 85) based on the clinical appearance and the dermoscopic images taken. In addition, the lengths of lesions will be measured at the corresponding visits.

Original interventions:

Topical artemether formulation

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Artemether

Primary outcome measure

1. Regression of lesions by assessing the lesions with a 6-point IGA (Investigator Global Assessment) Score at baseline, 56 and 85 days
2. Reduction of lesion size by measuring the longest axis (mm) of the lesion at baseline visit (V1) and at baseline, 56 and 85 days

Secondary outcome measures

therapy outcome, i.e. the IGA (investigator global assessment) score and lengths of treated lesions versus reference (not treated) lesions at 56 and 85 days.

Overall study start date

02/02/2015

Completion date

31/07/2015

Eligibility

Key inclusion criteria

1. Age above 40 years old
2. Phototype II, III and IV
3. At least 8 flat or slightly elevated SK lesions with a "pasted-on" look and typical characteristics
4. Lesion size: longest axis (dimension) 2 mm to 10mm
5. Willingness to participate in the study and to comply with the study protocol
6. Written informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

15

Key exclusion criteria

1. Presence of pregnancy, lactation, childbearing potential without contraception
2. Female participants of childbearing potential not using and not willing to continue using a medically reliable method of contraception
4. SK lesion close to the eye or mucosa (mouth, genitals)
5. Lesion in a skin fold or an area where clothing (e.g. belt) may cause physical irritation
6. Pedunculated, verrucous, papilomatous and irritated lesions
7. Presence of clinically significant skin or systemic disease
8. Pathological findings at screening (melanoma, lentigo maligna, inflammation, bleeding)
9. Concomitant participation in another study
10. Traveling to regions with endemic malaria
11. Previous use of treatment of the lesions within 2 years prior to visit 1
12. Known or suspected non-compliance, drug or alcohol abuse
13. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
14. Enrolment of the investigator, his/her family members, employees and other dependent persons

Date of first enrolment

20/02/2015

Date of final enrolment

30/03/2015

Locations

Countries of recruitment

Switzerland

Study participating centre

Somamedica AG

Zollikerstrasse 106

Zollikon

Switzerland

8702

Sponsor information**Organisation**

EpiPharm AG

Sponsor details

Hauptstrasse 67

Binningen

Switzerland

4102

Sponsor type

Industry

ROR

<https://ror.org/040fx6j66>

Funder(s)**Funder type**

Industry

Funder Name

EpiPharm AG

Results and Publications**Publication and dissemination plan**

Publication planned in a peer reviewed journal .

Intention to publish date

30/06/2017

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available